Published in Fitness and Wellness Business Week, February 9th, 2005
This compound is a selective agonist of 5-HT2C serotonin receptors, which are concentrated in the hypothalamus, an area of the brain known to play an important role in regulating food intake and metabolism.
This phase II clinical trial of APD356 is a randomized, double-blinded, multiple-dose, 28-day trial examining 400 obese volunteers. Arena expects that the trial will compare doses of 1, 5 and 15 mg of APD356 to a placebo and will...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Fitness and Wellness Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.